Over 50 Meetings with Global Pharmaceutical Companies in New York
CEO John Rim Attends to Discuss Strategic Partnerships
Continued Participation in International Events Including AACR and PEGS

Samsung Biologics announced on the 25th that it is strengthening its global contract acquisition efforts by participating in "DCAT Week 2026," held in New York, USA from March 23 to 26 (local time).


DCAT Week is a global pharmaceutical and biotechnology networking event that began in 1890 under the auspices of the New York Chamber of Commerce. It is now organized annually by the DCAT Association and is recognized as the optimal event for corporate partnership discussions, as more than 90% of attendees are high-level executives with decision-making authority.


Kevin Sharp, Vice President of Sales and Operations at Samsung Biologics Sales Center, is presenting at the member company announcement forum held on the 23rd (local time). Samsung Biologics

Kevin Sharp, Vice President of Sales and Operations at Samsung Biologics Sales Center, is presenting at the member company announcement forum held on the 23rd (local time). Samsung Biologics

View original image

Except for 2020, when the event was not held due to COVID-19, Samsung Biologics has participated in DCAT Week for 11 consecutive years since 2016. This year as well, the company has prepared a dedicated meeting room in a prime location at the venue and plans to hold more than 50 business meetings with global pharmaceutical companies. CEO John Rim is also attending the event to discuss strategic partnerships with key industry figures.


On the first day of the event, March 23, Kevin Sharp, Vice President of Sales and Operations at the Samsung Biologics Sales Center, participated as a speaker at the member company announcement forum. Vice President Sharp shared recent achievements under the theme of "Expanding Production Capacity and Network Development," including the acquisition of the Rockville plant, the purchase of the third Bio Campus site, an open innovation partnership with Eli Lilly, and a vaccine production partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).


Samsung Biologics also conducted activities in parallel to enhance brand awareness as a top-tier global contract development and manufacturing organization (CDMO). The company participated as a co-sponsor for a presentation session held the previous day, promoting its CDMO competitiveness before and after the session. In addition, it installed banners and promotional materials at the event venue to further increase brand recognition. At the main DCAT Week dinner event on March 26, Samsung Biologics will join other global CDMO companies such as Lonza and Thermo Fisher Scientific as a sponsor.



In addition to DCAT Week, Samsung Biologics is also scheduled to participate in other major global events, including the American Association for Cancer Research (AACR 2026) Annual Meeting to be held next month in San Diego, USA, and the PEGS Boston Summit taking place in Boston in May.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing